Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial ( EMPA‐ELDERLY )

AimUse of sodium‐glucose co‐transporter‐2 inhibitors (SGLT2is) for glycaemic control is increasing in individuals with type 2 diabetes (T2D) for their additional benefits on heart failure and chronic kidney disease. However, SGLT2is generally reduce body weight, which might promote sarcopenia in old...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2023-12, Vol.25 (12), p.3538-3548
Main Authors: Yabe, Daisuke, Shiki, Kosuke, Homma, Gosuke, Meinicke, Thomas, Ogura, Yuji, Seino, Yutaka
Format: Article
Language:English
Subjects:
Antidiabetics
Body fat
Body mass index
Body weight
Clinical trials
Congestive heart failure
Diabetes
Diabetes mellitus (non-insulin dependent)
Double-blind studies
Glucose
Glucose transporter
Hemoglobin
Kidney diseases
Placebos
Renal failure
Sarcopenia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!